AFT-58 (SOLTI-2101): A Phase III, Multicenter, Open-Label Study of Ribociclib vs. Palbociclib in Patients with Advanced Hormone Receptor-Positive/HER2-negative/HER2-Enriched Breast Cancer, Harmonia TrialAFT-58 (SOLTI-2101): A Phase III, Multicenter, Open-

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science